- Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN
- ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
On 6ix: 6ix.com/news/vera-therapeutics-submits-biologics-license-application-us-fda-through-accelerated
Watch Vera Therapeutics' latest callVera Therapeutics (NASDAQ:VERA) Q3 2026 Earnings Call · Replay · Nov 5Read the transcript of Vera Therapeutics (NASDAQ:VERA) Q3 2026 Earnings CallVera Therapeutics, Inc. on 6ix
In the deck
Story so far
- Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
- Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
Earlier from Vera Therapeutics
- Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
- Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
- Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4: 30 pm ET
- Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Later from Vera Therapeutics
- Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
- Vera Therapeutics to Participate at Upcoming Investor Conferences
- Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
Follow Vera Therapeutics into a list and get an email when it puts out news.
Follow Vera Therapeutics